Glycated albumin in pregnancy: reference intervals establishment and its predictive value in adverse pregnancy outcomes

Table 3 Comparisons of glycated albumin of pregnant women with and without adverse pregnancy outcomes

	Case N/total	Control N/total	Odds ratio	P-value
Non-GDM group (n = 327)
Preterm delivery	0/5	4/322	0.00	1.00
Postpartum hemorrhage	0/14	4/313	0.00	1.00
Preeclampsia	0/16	4/311	0.00	1.00
Hypertension	0/69	4/258	0.00	0.58
LGA	0/12	4/310	0.00	1.00
GDM group (n = 894)
Preterm delivery	13/63	212/831	0.76	0.40
Postpartum hemorrhage	37/160	118/734	1.57	0.03
Preeclampsia	10/60	215/834	0.58	0.12
Hypertension	9/45	180/849	0.93	0.85
LGA	31/114	181/717	1.11	0.66

case: patients with the specific adverse pregnancy outcome; control: patients without specific adverse pregnancy outcome. LGA: large for gestation age. N: the number of subjects with GlyA greater-than-upper-limit (13.09%). total: the total number of the subjects with (case) or without (control) specific adverse pregnancy outcome. Chi-square test was performed for P value calculation. For the LGA study, the subjects with preterm delivery were excluded

ISSN: 1471-2393